ReviewPharmacotherapy2020
Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.
Review in Pharmacotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis.European journal of clinical pharmacology · 2022Pooled it
- Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards: A Systematic Review.JAMA network open · 2021Pooled it
- Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.International journal of clinical practice · 2021Pooled it
- Clear Cell Ovarian Carcinoma and Its Distinct Coagulopathy Profile: Molecular Drivers and Clinical Implications.Cancer management and research · 2025Review
- National Trends in Anticoagulation Therapy for COVID-19 Hospitalized Adults in the United States: Analyses of the National COVID Cohort Collaborative.The Journal of infectious diseases · 2023Article
- COVID-19 and cardiovascular complications: updates of emergency medicine.Emergency and critical care medicine · 2023Article
- A systematic review on post-discharge venous thromboembolism prophylaxis in patients with COVID-19.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023Review
- The central role of neutrophil extracellular traps (NETs) and by-products in COVID-19 related pulmonary thrombosis.Immunity, inflammation and disease · 2023Review
- A review of venous thromboembolism in India.The Indian journal of medical research · 2023Review
- Onset timing and duration of augmented renal clearance in a mixed intensive care unit.Journal of intensive care · 2023Article
- Systemic reduced-dose alteplase for diffuse pulmonary thrombi in a COVID-19 patient.Clinical case reports · 2023Article
- Nasopharyngeal viral load at admission is not an independent predictor of thromboembolic complications in unvaccinated COVID-19 hospitalized patients.Journal of thrombosis and thrombolysis · 2023Article
- Virology and Molecular Pathogenesis of Coronavirus Disease 2019: An Update.The Eurasian journal of medicine · 2022Article
- Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation.International immunopharmacology · 2022Review
- Management of hip fracture in COVID-19 infected patients.World journal of orthopedics · 2022Review
- The Incidence of Venous Thromboembolism in Critically Ill Patients with SARS-CoV-2 Infection Compared with Critically Ill Influenza and Community-Acquired Pneumonia Patients: A Retrospective Chart Review.Medical sciences (Basel, Switzerland) · 2022Article
- An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).International immunopharmacology · 2022Review
- Renal consequences of the novel coronavirus disease 2019 (COVID-19) and hydrogen sulfide as a potential therapy.Nitric oxide : biology and chemistry · 2022Review
- Delayed diagnosis of homocystinuria presenting with coronavirus disease 2019 in a 17-year-old boy.Revista da Sociedade Brasileira de Medicina Tropical · 2022Article
- Association between Heparin Dose and 6-Week Mortality in Patients with COVID-19.Mediterranean journal of hematology and infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a worldwide pandemic, and patients with the infection are referred to as having COVID-19. Although COVID-19 is commonly considered a respiratory disease, there is clearly a thrombotic potential that was not expected. The pathophysiology of the disease and subsequent coagulopathy produce an inflammatory, hypercoagulable, and hypofibrinolytic state. Several observational studies have demonstrated surprisingly high rates of venous thromboembolism (VTE) in both general ward and intensive care patients with COVID-19. Many of these observational studies demonstrate high rates of VTE despite patients being on standard, or even higher intensity, pharmacologic VTE prophylaxis. Fibrinolytic therapy has also been used in patients with acute respiratory distress syndrome. Unfortunately, high quality randomized controlled trials are lacking. A literature search was performed to provide the most up-to-date information on the pathophysiology, coagulopathy, risk of VTE, and prevention and treatment of VTE in patients with COVID-19. These topics are reviewed in detail, along with practical issues of anticoagulant selection and duration. Although many international organizations have produced guidelines or consensus statements, they do not all cover the same issues regarding anticoagulant therapy for patients with COVID-19, and they do not all agree. These statements and the most recent literature are combined into a list of clinical considerations that clinicians can use for the prevention and treatment of VTE in patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.